Clinical Trial Update: Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating bortezomib, rituximab, dexamethasone with or without temsirolimus in untreated or relapsed Waldenström macroglobulinemia and relapsed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-05-05